Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Hospital Português, Salvador, Brazil.
Can J Gastroenterol Hepatol. 2021 Nov 10;2021:7746401. doi: 10.1155/2021/7746401. eCollection 2021.
Primary sclerosing cholangitis (PSC) is associated with a broad phenotypic spectrum in different populations from diverse ethnic and racial backgrounds. This study aimed to describe the clinical characteristics and outcomes of PSC in a multicenter cohort of patients from Brazil.
Data from the Brazilian Cholestasis Study Group were retrospectively reviewed to assess demographic information and clinical characteristics of PSC, as well as the outcomes, such as transplantation-free survival.
This cohort included 210 patients. After excluding 33 (15.7%) patients with PSC and overlap syndrome of autoimmune hepatitis, 177 (97 males, median age 33 (21-42) years) with clear-cut PSC were eligible for this study. Most of the patients ( = 139, 78.5%) were symptomatic, and 104 (58.7%) had advanced PSC at the time of diagnosis. Concurrent inflammatory bowel disease was observed in 78 (58.6%) of the investigated patients ( = 133), and most of them had ulcerative colitis ( = 61, 78.2%). The 1- and 5-year survival free of liver transplantation or death were 92.3 ± 2.1% and 66.9 ± 4.2%, respectively, and baseline advanced PSC, pruritus, and elevated bilirubin levels were independent risk factors for the composite adverse outcome. Females were significantly older and had lower bilirubin levels than males at baseline, but survival was not associated with sex. Approximately 12.4% ( = 22) of patients with PSC died, and 32.8% ( = 58) underwent liver transplantation at a median follow-up time of 5.3 and 3.2 years.
Multiethnic Brazilian PSC patients exhibited a less pronounced male predominance and a lower frequency of inflammatory bowel disease than Caucasians. Adverse outcomes were more frequent, probably due to advanced disease at baseline.
原发性硬化性胆管炎(PSC)在不同种族和背景的人群中表现出广泛的表型谱。本研究旨在描述巴西多中心队列患者的 PSC 临床特征和结局。
回顾性分析巴西胆病研究组的数据,以评估 PSC 的人口统计学信息和临床特征,以及结局,如无移植生存。
该队列包括 210 例患者。排除 33 例(15.7%)PSC 和自身免疫性肝炎重叠综合征患者后,177 例(97 例男性,中位年龄 33(21-42)岁)明确的 PSC 患者符合本研究标准。大多数患者( = 139,78.5%)有症状,104 例(58.7%)在诊断时已处于晚期 PSC。在研究的患者中观察到并发炎症性肠病( = 78,58.6%),其中大多数患者患有溃疡性结肠炎( = 61,78.2%)。无肝移植或死亡的 1 年和 5 年生存率分别为 92.3 ± 2.1%和 66.9 ± 4.2%,基线时晚期 PSC、瘙痒和胆红素升高是复合不良结局的独立危险因素。女性在基线时比男性年龄更大,胆红素水平更低,但生存与性别无关。约 12.4%( = 22)的 PSC 患者死亡,32.8%( = 58)在中位随访时间 5.3 和 3.2 年后接受了肝移植。
多民族巴西 PSC 患者表现出男性优势不明显,炎症性肠病发生率低于白种人。不良结局更为常见,可能是由于基线时疾病更为严重。